Fig. 1

Schematic presentation of current pre-clinically tested drugs in neuroblastoma. A discussed anti-tumor drugs used against neuroblastoma in vitro and/or in vitro, and their targets are presented. In addition, a connection between the molecular targets is determined by the arrows. Legend shows a type of interaction described between the molecules a Indicates targeting of MYCN and P53/MDM dependent pathways. b Depicts drugs against ALK, Trk and PI3K/AKT/mTOR pathway. c Illustrates a targeting of main anti-apoptotic molecules. Gene symbol and its corresponding protein: NTRK1 – TrkA; NTRK2 – TrkB; PIK3CA - PI3K, BIRC5 – Survivin (Data resource: http://www.pathwaycommons.org/)